Protocols for High-Risk Pregnancies, 7th Edition Prenatal testing for chromosomal abnormalities
Protocol 5 - In this protocol, Norton reviews the pathophysiology of fetal aneuploidy and the wide range of tests for it. Included are perspectives on cell-free DNA testing, first-trimester combined screening, nuchal translucency (NT) sonography, and pregnancy-associated plasma protein A (PAPP-A) and human chorionic gonadotropin (hCG), as well as quad marker screening in the second trimester in appropriate cases, and combined first- and second-trimester screening.
Trisomies 21, 18, and 13 are the most common autosomal trisomies. Triploidy and deletions and duplications of portions of chromosomes also occur. With the advent of chromosomal microarray analysis, it is now possible to identify submicroscopic abnormalities associated with significant genetic diseases.
Key Messages
- All pregnant women, regardless of their age, should be offered prenatal screening and diagnostic testing for detection of chromosomal abnormalities.
- Chorionic villus sampling is typically performed at 10 to 14 weeks’ gestation, whereas genetic amniocentesis is performed at 15 to 20 weeks.
- cfDNA testing, performed after
10 weeks’ gestation, is more than 99% accurate for detection of fetal trisomy 21 and 98% for trisomy 18 with a combined false-positive rate of 0.13% to 0.25%. - Expanded cfDNA panels, which are available from some laboratories, have not been clinically validated and are not recommended.
- About 85% of trisomy 21 cases can be detected at 10 to 14 weeks’ gestation, based on a combination of maternal age, NT sonography, PAPP-A, and hCG. NT sonography should be performed only by credentialed sonographers and physicians.
- Sonographic markers of aneuploidy that may be visible in the first trimester include cystic hygroma, absent nasal bone, abnormal Doppler blood flow in the ductus venosus, and abnormal blood flow across the tricuspid valve with evidence of tricuspid regurgitation. However, first-trimester evaluation for these secondary markers is not recommended for general population screening.
- The optimal time for a genetic sonogram is 18 to 22 weeks. Identification of a major structural malformation increases risk of trisomy 21 by
20- to 30-fold and should trigger
genetic amniocentesis. - Approaches to combined first- and second-trimester screening include sequential screening and integrated screening. A serum integrated screening approach has a relatively high detection rate but provides a
later result.
Study highlights need for interventions to prevent postpartum smoking relapse
January 21st 2025Smoking cessation during pregnancy not only reduces pregnancy complications but also lowers the risk of relapse and new smoking initiation in the first postpartum year, according to a recent study.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Multidisciplinary care found key to managing blood cancers during pregnancy
January 13th 2025Evidence-based guidelines stress the importance of timely diagnosis, collaborative care, and maternal-infant safety in addressing the rising incidence of hematological malignancies in pregnancy.
Read More
High opioid use disorder and severe maternal morbidity rates reported among Medicaid patients
January 8th 2025Pregnant patients with opioid use disorder enrolled in Medicaid face significantly increased risks of severe maternal morbidity, underscoring the need for targeted state Medicaid interventions.
Read More
